Cargando…
Putative Transcriptomic Biomarkers in the Inflammatory Cytokine Pathway Differentiate Major Depressive Disorder Patients from Control Subjects and Bipolar Disorder Patients
Mood disorders consist of two etiologically related, but distinctly treated illnesses, major depressive disorder (MDD) and bipolar disorder (BPD). These disorders share similarities in their clinical presentation, and thus show high rates of misdiagnosis. Recent research has revealed significant tra...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949789/ https://www.ncbi.nlm.nih.gov/pubmed/24618828 http://dx.doi.org/10.1371/journal.pone.0091076 |
_version_ | 1782306937031884800 |
---|---|
author | Powell, Timothy R. McGuffin, Peter D'Souza, Ursula M. Cohen-Woods, Sarah Hosang, Georgina M. Martin, Charlotte Matthews, Keith Day, Richard K. Farmer, Anne E. Tansey, Katherine E. Schalkwyk, Leonard C. |
author_facet | Powell, Timothy R. McGuffin, Peter D'Souza, Ursula M. Cohen-Woods, Sarah Hosang, Georgina M. Martin, Charlotte Matthews, Keith Day, Richard K. Farmer, Anne E. Tansey, Katherine E. Schalkwyk, Leonard C. |
author_sort | Powell, Timothy R. |
collection | PubMed |
description | Mood disorders consist of two etiologically related, but distinctly treated illnesses, major depressive disorder (MDD) and bipolar disorder (BPD). These disorders share similarities in their clinical presentation, and thus show high rates of misdiagnosis. Recent research has revealed significant transcriptional differences within the inflammatory cytokine pathway between MDD patients and controls, and between BPD patients and controls, suggesting this pathway may possess important biomarker properties. This exploratory study attempts to identify disorder-specific transcriptional biomarkers within the inflammatory cytokine pathway, which can distinguish between control subjects, MDD patients and BPD patients. This is achieved using RNA extracted from subject blood and applying synthesized complementary DNA to quantitative PCR arrays containing primers for 87 inflammation-related genes. Initially, we use ANOVA to test for transcriptional differences in a ‘discovery cohort’ (total n = 90) and then we use t-tests to assess the reliability of any identified transcriptional differences in a ‘validation cohort’ (total n = 35). The two most robust and reliable biomarkers identified across both the discovery and validation cohort were Chemokine (C-C motif) ligand 24 (CCL24) which was consistently transcribed higher amongst MDD patients relative to controls and BPD patients, and C-C chemokine receptor type 6 (CCR6) which was consistently more lowly transcribed amongst MDD patients relative to controls. Results detailed here provide preliminary evidence that transcriptional measures within inflammation-related genes might be useful in aiding clinical diagnostic decision-making processes. Future research should aim to replicate findings detailed in this exploratory study in a larger medication-free sample and examine whether identified biomarkers could be used prospectively to aid clinical diagnosis. |
format | Online Article Text |
id | pubmed-3949789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-39497892014-03-12 Putative Transcriptomic Biomarkers in the Inflammatory Cytokine Pathway Differentiate Major Depressive Disorder Patients from Control Subjects and Bipolar Disorder Patients Powell, Timothy R. McGuffin, Peter D'Souza, Ursula M. Cohen-Woods, Sarah Hosang, Georgina M. Martin, Charlotte Matthews, Keith Day, Richard K. Farmer, Anne E. Tansey, Katherine E. Schalkwyk, Leonard C. PLoS One Research Article Mood disorders consist of two etiologically related, but distinctly treated illnesses, major depressive disorder (MDD) and bipolar disorder (BPD). These disorders share similarities in their clinical presentation, and thus show high rates of misdiagnosis. Recent research has revealed significant transcriptional differences within the inflammatory cytokine pathway between MDD patients and controls, and between BPD patients and controls, suggesting this pathway may possess important biomarker properties. This exploratory study attempts to identify disorder-specific transcriptional biomarkers within the inflammatory cytokine pathway, which can distinguish between control subjects, MDD patients and BPD patients. This is achieved using RNA extracted from subject blood and applying synthesized complementary DNA to quantitative PCR arrays containing primers for 87 inflammation-related genes. Initially, we use ANOVA to test for transcriptional differences in a ‘discovery cohort’ (total n = 90) and then we use t-tests to assess the reliability of any identified transcriptional differences in a ‘validation cohort’ (total n = 35). The two most robust and reliable biomarkers identified across both the discovery and validation cohort were Chemokine (C-C motif) ligand 24 (CCL24) which was consistently transcribed higher amongst MDD patients relative to controls and BPD patients, and C-C chemokine receptor type 6 (CCR6) which was consistently more lowly transcribed amongst MDD patients relative to controls. Results detailed here provide preliminary evidence that transcriptional measures within inflammation-related genes might be useful in aiding clinical diagnostic decision-making processes. Future research should aim to replicate findings detailed in this exploratory study in a larger medication-free sample and examine whether identified biomarkers could be used prospectively to aid clinical diagnosis. Public Library of Science 2014-03-11 /pmc/articles/PMC3949789/ /pubmed/24618828 http://dx.doi.org/10.1371/journal.pone.0091076 Text en © 2014 Powell et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Powell, Timothy R. McGuffin, Peter D'Souza, Ursula M. Cohen-Woods, Sarah Hosang, Georgina M. Martin, Charlotte Matthews, Keith Day, Richard K. Farmer, Anne E. Tansey, Katherine E. Schalkwyk, Leonard C. Putative Transcriptomic Biomarkers in the Inflammatory Cytokine Pathway Differentiate Major Depressive Disorder Patients from Control Subjects and Bipolar Disorder Patients |
title | Putative Transcriptomic Biomarkers in the Inflammatory Cytokine Pathway Differentiate Major Depressive Disorder Patients from Control Subjects and Bipolar Disorder Patients |
title_full | Putative Transcriptomic Biomarkers in the Inflammatory Cytokine Pathway Differentiate Major Depressive Disorder Patients from Control Subjects and Bipolar Disorder Patients |
title_fullStr | Putative Transcriptomic Biomarkers in the Inflammatory Cytokine Pathway Differentiate Major Depressive Disorder Patients from Control Subjects and Bipolar Disorder Patients |
title_full_unstemmed | Putative Transcriptomic Biomarkers in the Inflammatory Cytokine Pathway Differentiate Major Depressive Disorder Patients from Control Subjects and Bipolar Disorder Patients |
title_short | Putative Transcriptomic Biomarkers in the Inflammatory Cytokine Pathway Differentiate Major Depressive Disorder Patients from Control Subjects and Bipolar Disorder Patients |
title_sort | putative transcriptomic biomarkers in the inflammatory cytokine pathway differentiate major depressive disorder patients from control subjects and bipolar disorder patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949789/ https://www.ncbi.nlm.nih.gov/pubmed/24618828 http://dx.doi.org/10.1371/journal.pone.0091076 |
work_keys_str_mv | AT powelltimothyr putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients AT mcguffinpeter putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients AT dsouzaursulam putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients AT cohenwoodssarah putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients AT hosanggeorginam putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients AT martincharlotte putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients AT matthewskeith putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients AT dayrichardk putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients AT farmerannee putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients AT tanseykatherinee putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients AT schalkwykleonardc putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients |